【明理講堂2024年第57期】
報告題目：What is the value of evaluating health technologies?
時間：2024年9月18號 下午16:30-17:30
地點：偉德國際1946bv官網中關村校區主樓409
報告人：Alexander David Morton
報告人簡介：
Alec Morton is Prof of Management Science at the University of Strathclyde and Visiting Professor in the School of Public Health at NUS. He has degrees from the University of Manchester and the University of Strathclyde. He has worked for Singapore Airlines, and the London School of Economics, has held visiting positions at Carnegie Mellon University in Pittsburgh, Aalto University in Helsinki, the University of Science and Technology of China (USTC) in Hefei, and the National Audit Office and is a member of the International Decision Support Initiative. His main interests are in decision analysis and health economics. His research is funded by the European Commission, the Department of Health, the Medical Research Council and Engineering and Physical Sciences Research Council, and the Chief Scientist's Office of the Scottish NHS. Alec has been active in the INFORMS Decision Analysis Society, EURO and ISPOR. He is on the Editorial Board of Decision Analysis and is an Associate Editor for the EURO Journal on Decision Processes, the Transactions of the Institute of Industrial Engineers, and OR Spectrum. Past consulting clients include the National Audit Office, the Department of Health, the Environment Agency, the Nuclear Decommissioning Authority and the Global Fund to Fight AIDS, Tuberculosis & Malaria. His papers have won awards from the International Society for Pharmacoeconomics and Outcomes Research and the Society for Risk Analysis. His book Portfolio Decision Analysis with Jeff Keisler and Ahti Salo won the INFORMS Decision Analysis Society publication award in 2013 and his paper "CUT: A Multicriteria Approach for Concavifiable Preferences" (with Nikos Argyris and Jose Figueira) was a finalist for the same prize in 2016.
報告內容簡介：
Many countries have adopted Health Technology Assessment (HTA), often including some form of cost-effectiveness analysis, as a way of prioritising investment in health technologies and identifying a high value and financially sustainable development path for their health systems. But how should HTA institutions themselves be evaluated? In this talk we take both qualitative and quantitative approaches to this question. For the qualitative part, we report on a programme of interviews with senior figures in the international HTA community. Our research highlights the importance of broadening out the evaluation framework from a narrow focus on whether HTA reports have been implemented to look at perceptions of and benefits to different system stakeholders, including providers, payers, patients and the public, Ministries of Health and Finance and the scientific community. For the quantitative part of the talk, we describe a simulation model which can be used to quantify the benefits of implementing a cost-effectiveness decision rule to prioritise health technologies over a counterfactual scenario of no prioritization, with parameterisations based on datasets from the UK, Malawi and Thailand. Our simulations show that while using cost effectiveness analysis may lead to lower costs or more health, or both, it can never lead to more cost and less health.
